[1] |
Berends A, Buitenwerf E, de KR, et al. Incidence of pheochromocy-toma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review[J]. Eur J Intern Med, 2018, 62(3): 51-8.
|
[2] |
Iacobone M, Belluzzi S. Surgical approaches and results of treatment for hereditary paragangliomas[J]. Res Clin Endocrinol Metab, 2019, 122(35): 101298-307.
|
[3] |
Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine[J]. Nat Rev Endocrinol, 2015, 11(2): 101-11. doi: 10.1038/nrendo.2014.188
|
[4] |
Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J]. J Clin Oncol, 2008, 26(18): 3063-72. doi: 10.1200/JCO.2007.15.4377
|
[5] |
Kiernan CM, Solórzano CC. Pheochromocytoma and paraganglioma: diagnosis,genetics,and treatment[J]. Surg Oncol Clin.N, 2016, 25(2): 119-38. doi: 10.1016/j.suronc.2016.04.002
|
[6] |
Muñoz-Largacha JA, Glocker RJ, Moalem J, et al. Incidental posterior mediastinal paraganglioma: the safe approach to management,case report[J]. Int J Surg Case Rep, 2017, 35(1): 25-8.
|
[7] |
Därr, R, Ku hn, et al. Accuracy of recommended sampling and assay methods for the determination of plasma-free and urinary fractionated metanephrines in the diagnosis of pheochromocytoma and paraganglioma: a systematic review[J]. Endocrine, 2017, 56(3): 495-503. doi: 10.1007/s12020-017-1300-y
|
[8] |
Manu P, Runge LA. Biochemical screening for pheochromo-cytoma superiority of urinary metanephrines measurements[J]. Am J Epidemiol, 1984, 120(5): 788-90. doi: 10.1093/oxfordjournals.aje.a113947
|
[9] |
Hartmut PN, Din M, William FY, et al. Pheochromocytoma and paraganglioma[J]. N Engl J Med, 2019, 381(14): 552-65.
|
[10] |
Lauren F. Pheochromocytoma and paraganglioma: genetics,diagnosis, and treatment[J]. Hematol Oncol Clin North Am, 2016, 30(3): 135-50.
|
[11] |
Manisha HS, Whitney SG. Neuroedocrine and adrenal tumors[OL]. NCCN guidelines, 2019.
|
[12] |
Shindorf LM, Chaudhuri B, et al. Single-agent thalidomide for treatment of malignant paraganglioma of the organ of zuckerkandl[J]. Case Rep Med, 2019, 75(8): 1-4.
|
[13] |
Niemeijer ND, Alblas G, van HT, et al. Chemotherapy with cyclophosphamide,vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis[J]. Clin Endocrinol (Oxf), 2014, 81(5): 642-51. doi: 10.1111/cen.12542
|
[14] |
Gulenchyn KY, Yao X, Asa SL, et al. Radionuclide therapy in neuroendocrine tumours: a systematic review[J]. Clin Oncol (R Coll Radiol), 2012, 24(9): 294-308.
|
[15] |
Wfj Y. Endocrine hypertension in Melmed[C]. 2016.
|
[16] |
Groeben H, Nottebaum BJ, Alesina PF, et al. Peri-operative α-receptor blockade in phaeo-chromocytoma surgery: an observational case series[J]. Br J Anaesth, 2017, 45(3): 118-29.
|
[17] |
Amar L, Baudin E, Burnichon N, et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas[J]. J Clin Endocrinol Metab, 2007, 92(11): 3822-8.
|
[18] |
Hamidi O, Young WF, Iñiguez-Ariza I, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years[J]. J Clin Endocrinol Metab, 2017, 102(9): 3296-305. doi: 10.1210/jc.2017-00992
|
[19] |
Rafat C, Zinzindohoue F, Hernigou A, et al. Peritoneal implantation of pheo-chromocytoma following tumor capsule rupture during surgery[J]. J Clin Endocrinol Metab, 2014, 51(10): 99-107.
|
[20] |
Plouin PF, Amar L, Dekkers OM, et al. European society of endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma[J]. J Endocrinol, 2016, 174(3): G1-10.
|
[21] |
Crona J, David T, Karel P. New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification[J]. Endocr Rev, 2017, 38(12): 489-515.
|